The homogeneous and heterogeneous risk factors for occurrence and prognosis in lung cancer patients with bone metastasis

Abstract Purpose: A comprehensive population-based study on risk and prognostic factors of lung cancer with brain metastasis is lacking. Methods: 95191 patients diagnosed with lung cancer between 2010 and 2017 were collected from the Surveillance, Epidemiology and End Results (SEER) database. Patients were stratified by different variables. Multivariable logistic and Cox regression were applied to analyze the risk and prognostic factors of brain metastasis among lung cancer patients, respectively. The Fine and Gray’s competing risk regression model was performed to obtain prognostic factors associated with cancer-specific mortality.Results: Among the 95191 patients diagnosed with lung cancer, 10765 patients have brain metastasis, with a metastatic incidence of 11.31%. The primary site of tumor, residence type, age, histological type, race and extracranial metastasis were all independent risk factors of brain metastasis. Compared with other histological types, small cell lung cancer displayed a highest incidence of brain metastasis (16.62%). The median overall survival (OS) among lung cancer patients with brain metastasis was only 6.05 months. The primary site of tumor, median household income, age, histological type, race, gender and extracranial metastasis were all associated with the prognosis of brain metastasis. Patients with squamous cell carcinoma had the worst prognosis, the median OS was only 3.68 months. And our established new nomogram showed a good discriminative ability on predicting the probability of cancer-specific survival among patients with brain metastasis, the C-index was 0.61.Conclusion: Our study provided a deeper insight into the risk factors and prognosis of brain metastasis among lung cancer patients.

Download Full-text

P2.16-13 Risk Factors of Radiation Pneumonitis in Lung Cancer Patients with Subclinical Interstitial Lung Disease After Thoracic Radiotherapy

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.08.1880 ◽

2019 ◽

Vol 14 (10) ◽

pp. S870

Author(s):

F. Li ◽

S. Liang ◽

H. Wu ◽

Y. Xu ◽

M. Chen

Keyword(s):

Risk Factors ◽

Lung Cancer ◽

Interstitial Lung Disease ◽

Lung Disease ◽

Cancer Patients ◽

Radiation Pneumonitis ◽

Thoracic Radiotherapy ◽

Lung Cancer Patients

Download Full-text

Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study

Clinical Infectious Diseases ◽

10.1093/cid/ciaa802 ◽

2020 ◽

Cited By ~ 1

Author(s):

Alexandre E Malek ◽

Melissa Khalil ◽

Ray Hachem ◽

Anne Marie Chaftari ◽

Johny Fares ◽

...

Keyword(s):

Risk Factors ◽

Lung Cancer ◽

Urinary Tract ◽

Cancer Treatment ◽

Cancer Patients ◽

Checkpoint Inhibitor ◽

Advanced Lung Cancer ◽

Lung Cancer Patients ◽

Independent Risk Factors ◽

Tract Infections

Abstract Background Checkpoint inhibitor (CPI) immunotherapy has revolutionized cancer treatment. However, immune-related adverse events and the risk of infections are not well studied. To assess the infectious risk of CPIs, we evaluated the incidence of infections in lung cancer patients treated with CPIs plus conventional chemotherapy (CC) vs CC alone. Methods We performed a retrospective comparative study of patients with advanced non–small cell lung cancer who received CPIs combined with CC and those treated with CC alone at our institution during January 2016 to February 2019. We compared clinical characteristics, treatments, and outcomes including infection rate and mortality between the groups. Results We identified 123 patients for the CPI group and 147 patients for the control (CC) group. Eighteen patients (15%) in the CPI group and 33 patients (22%) in the control group developed infections (P = .1). Pneumonia was the most common infection encountered in both groups. Urinary tract infection was higher in the CC group (40%) than in the CPI group (9%) (P = .01). On multivariable analysis, chronic obstructive pulmonary disease (P = .024), prior use of corticosteroids (P = .021), and neutropenia (P < .001) were independent risk factors for infection and severe infection requiring hospital admission. Chronic kidney disease (P = .02), prior cancer treatment (P = .023), and neutropenia (P < .0001) were identified as independent risk factors for all-cause mortality. Conclusions Lung cancer patients treated with CPIs combined with CC have a comparable risk of infection to those treated with CC alone, although there is a trend towards fewer infections in those given CPIs, particularly when it comes to urinary tract infections.

Download Full-text